CIC
CRSP icon

Carnegie Investment Counsel’s CRISPR Therapeutics CRSP Stock Holding History

Carnegie Investment Counsel’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-102,112
Closed -$5.52M – 468
2024
Q2 		$5.52M Buy
102,112
+34,500
+51% +$2M 0.17% 131
2024
Q1 		$4.61M Sell
67,612
-5,925
-8% -$424K 0.14% 147
2023
Q4 		$4.6M Sell
73,537
-15,180
-17% -$839K 0.16% 143
2023
Q3 		$4.03M Buy
88,717
+27,875
+46% +$1.44M 0.15% 145
2023
Q2 		$3.42M Buy
+60,842
New +$3.45M 0.13% 157
2023
Q1 		– Sell
-25,682
Closed -$1.04M – 509
2022
Q4 		$1.04M Sell
25,682
-32,700
-56% -$1.73M 0.04% 274
2022
Q3 		$3.81M Sell
58,382
-28,770
-33% -$2.08M 0.18% 133
2022
Q2 		$5.3M Buy
87,152
+989
+1% +$58.1K 0.24% 112
2022
Q1 		$5.41M Sell
86,163
-32,189
-27% -$2.02M 0.2% 128
2021
Q4 		$8.97M Sell
118,352
-575
-0.5% -$50.2K 0.3% 99
2021
Q3 		$13.3M Buy
118,927
+1,755
+1% +$220K 0.5% 67
2021
Q2 		$19M Buy
117,172
+7,691
+7% +$935K 0.72% 48
2021
Q1 		$13.3M Buy
109,481
+15,289
+16% +$2.31M 0.56% 57
2020
Q4 		$14.4M Buy
94,192
+4,927
+6% +$582K 0.65% 52
2020
Q3 		$7.47M Sell
89,265
-2,455
-3% -$218K 0.38% 84
2020
Q2 		$6.74M Buy
91,720
+25,460
+38% +$1.49M 0.39% 79
2020
Q1 		$2.81M Buy
66,260
+28,650
+76% +$1.48M 0.2% 124
2019
Q4 		$2.29M Buy
37,610
+12,440
+49% +$679K 0.13% 155
2019
Q3 		$1.03M Buy
25,170
+2,570
+11% +$123K 0.07% 216
2019
Q2 		$1.06M Buy
+22,600
New +$903K 0.07% 210

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Carnegie Investment Counsel's CRSP Position: Q3 2024 in Review

Carnegie Investment Counsel sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 102,112 shares — an estimated $5.52M sold.

Carnegie Investment Counsel first reported a position in CRSP in Q2 2019 and held it in 20 quarters. The position peaked at $19M in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Carnegie Investment Counsel reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Carnegie Investment Counsel sold 102,112 CRISPR Therapeutics shares in Q3 2024, an estimated $5.52M.
  • Carnegie Investment Counsel first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 20 quarters.
  • Carnegie Investment Counsel's CRISPR Therapeutics position peaked at $19M in Q2 2021.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Carnegie Investment Counsel's 13F filing for Q3 2024, filed 10 Oct 2024.